PJC 58.61 Piper Jaffray Companies $PJC Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 2:09 PM

PJC 58.61 Piper Jaffray Companies $PJC Hit a 52 week high of 59.00 Currently at 58.61 -0.37 -0.63% With a day low of 58.61 and a total volume of 2,565.

PJC Piper Jaffray Companies Recent Headline News

Insider Trading Alert - PJC, SMCI And ARE Traded By Insiders
at The Street - 2 hrs 38 mins ago
Stocks with insider trader activity include PJC, SMCI and ARE
SMCI: 33.85 (+0.15), ARE: 83.40 (-0.34), PJC: 58.76 (-0.22)

Piper Jaffray Up 13.6% Since SmarTrend Uptrend Call (PJC)
Comtex SmarTrend(R) - Tue Nov 11, 9:25AM CST
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on October 23rd, 2014 at $51.93. In approximately 3 weeks, Piper Jaffray has returned 13.61% as of today's recent price of $59.00.
PJC: 58.76 (-0.22)

Investment Technology Group (ITG) Jumps: Stock Rises 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:32AM CST
Investment Technology Group Inc. (ITG) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
ITG: 19.87 (+0.10), PJC: 58.76 (-0.22), AI: 27.31 (-0.20), BGCP: 8.56 (-0.02)

Piper Jaffray Companies' (PJC) CEO Andrew Duff on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 23, 3:10PM CDT

PJC: 58.76 (-0.22)

NYSE stocks posting largest percentage increases
AP - Thu Oct 23, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at 1 p.m.:
CRS: 51.52 (+0.04), UFS: 40.45 (-0.50), CLV: 10.20 (-0.44), BBW: 18.49 (+0.49), PJC: 58.76 (-0.22), CLF: 10.81 (-0.23), MTRN: 38.33 (+0.04), XRS: 32.36 (-0.62), GPI: 87.21 (+0.67), BRP: 23.48 (+0.14), UIS: 27.68 (+0.31), SIX: 40.14 (+0.21), DF: 16.28 (-0.12)

Piper Jaffray beats by $0.46, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 7:04AM CDT

PJC: 58.76 (-0.22)

Piper Jaffray Companies Announces 2014 Third Quarter Results
Business Wire - Thu Oct 23, 7:03AM CDT
Piper Jaffray Companies (NYSE: PJC) today announced its financial results for the quarter ended September 30, 2014.
PJC: 58.76 (-0.22)

Piper Jaffray Companies to Hold Management Conference Call to Discuss 2014 Third Quarter Results
Business Wire - Wed Oct 15, 11:14AM CDT
Piper Jaffray (NYSE

JC) announced today that it will release its 2014 third quarter results prior to the opening of the market on Thursday, October 23, 2014. The company will also hold a conference call to review the financial results at 9:00 a.m. ET (8:00 a.m. CT). Andrew S. Duff, chairman and chief executive officer, and Debbra L. Schoneman, chief financial officer, will host the call.
PJC: 58.76 (-0.22)

Can Schwab Beat Wall St. For 5 Quarters In A Row?
at Investor's Business Daily - Mon Oct 13, 3:12PM CDT
Recent market choppiness has swamped Charles Schwab along with other brokers. With the waters muddied, it's not clear whether Schwab's earnings will be strong enough to meet or beat Wall Street expectations. The discount broker reports third-quarter...
RJF: 57.40 (+0.39), PJC: 58.76 (-0.22), AMP: 130.25 (+0.09), SCHW: 28.94 (+0.02)

Different is the New Cool, According to Piper Jaffray Survey of 7,200 Teens
Business Wire - Wed Oct 08, 10:00AM CDT
Piper Jaffray (NYSE: PJC) has completed its 28th semi-annual Taking Stock With Teens market research project, which indicates increased spending across categories despite decreased optimism about the economy.
PJC: 58.76 (-0.22)

Uptrend Call Working As Piper Jaffray Stock Rises 23.0% (PJC)
Comtex SmarTrend(R) - Thu Sep 25, 4:43PM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 22.96% as of today's recent price of $54.76.
PJC: 58.76 (-0.22)

Piper Jaffray Hits 52-Week High on Capital Market Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 1:58PM CDT
Shares of Piper Jaffray Companies (PJC) crafted a new 52-week high, touching $56.40 on Sep 17.
MRCC: 14.14 (+0.20), PJC: 58.76 (-0.22), AI: 27.31 (-0.20), MC: 34.92 (+1.50)

Piper Jaffray Shares Up 27.0% Since SmarTrend's Buy Recommendation (PJC)
Comtex SmarTrend(R) - Thu Sep 18, 11:04AM CDT
SmarTrend identified an Uptrend for Piper Jaffray (NYSE

JC) on April 25th, 2014 at $44.54. In approximately 5 months, Piper Jaffray has returned 26.96% as of today's recent price of $56.54.
PJC: 58.76 (-0.22)

Schwab's August DATs Witness Marginal Y/Y Decline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 4:50PM CDT
Schwab (SCHW) recorded Daily Average Trades of 460,000 for Aug 2014, reflecting a decline of 1% from the prior-year month and remaining same as that of the prior month.
PJC: 58.76 (-0.22), AI: 27.31 (-0.20), MC: 34.92 (+1.50), SCHW: 28.94 (+0.02)

CIT Group Grows Inorganically: Right Time to Buy the Stock? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 10:40AM CDT
CIT Group Inc. (CIT) has come a long way since its emergence from bankruptcy in 2009. The company is presently focused on growing inorganically.
PJC: 58.76 (-0.22), AI: 27.31 (-0.20), MC: 34.92 (+1.50), CIT: 49.15 (+0.04)

E*TRADE Financial (ETFC) August DARTs Descend 5% Q/Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:40AM CDT
Online brokerage firm, E*TRADE Financial Corporation (ETFC) reported a decline in its Daily Average Revenue Trades (DARTs) for Aug 2014.
PJC: 58.76 (-0.22), ETFC: 23.08 (+0.19), AMTD: 35.31 (+0.25), SCHW: 28.94 (+0.02)

How Will Visa (V) Stock Respond To These Coverage Initiations?
at The Street - Tue Sep 16, 7:44AM CDT
Visa (V) stock is up in pre-market trade after the financial company had coverage initiated at Sterne Agee, Bernstein and Piper Jaffray (PJC).
V: 249.33 (-0.88), PJC: 58.76 (-0.22)

Morgan Stanley to Phase Out Managed Mutual Fund Platform - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:50PM CDT
Morgan Stanley (MS), the world's largest seller of managed accounts, is phasing out a managed mutual fund program.
PJC: 58.76 (-0.22), AI: 27.31 (-0.20), BAC: 17.35 (-0.02), MS: 35.80 (-0.08)

Capital One's Expenses on Downward Trail, Revenues Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:25PM CDT
Capital One exhibits prudent expense management and remains strong in its Credit Card business. However, slump in overall revenues remains a major concern.
COF: 82.26 (-0.98), PJC: 58.76 (-0.22), HSBC: 50.59 (+0.22), AI: 27.31 (-0.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Love Business Group Helps SMEs Navigate Broadband Choices

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...